The inspection has concluded successfully on 1st September 2023 without any critical/major observation
The company has secured 506 marketing approvals for its oncology products across 76 countries.
Acquisition of biologics manufacturing facility in Bangalore to complete by the end of the third quarter in FY 24
The 'A+' rating reflects IOL's robust business model, diversified product portfolio
Investment enables development of revolutionary multi-omic platform using super-resolution imaging technology for earlier disease detection and accelerated discovery of therapeutics
_256_384.jpeg)
Launched Pathology Laboratory in Vijayawada offering a wide range of best-in-class diagnostic services with over 2500+ tests
Indoco expects this change in compliance status to pave the way for approvals of ANDAs submitted from this site.
Cooperative agreement with U.S. Government to advance U.S. biopharma industry and ensure pandemic preparedness
Marksans will continue to supply existing products until the end of 2023 to Teva's affiliates, ensuring high-quality standards
Subscribe To Our Newsletter & Stay Updated
